Midi Health Reviews and Complaints: Is It Actually Legit?

Is Midi Health a scam, or a real company?

Midi Health is a real company, not a scam. It was founded in 2021 and operates as Midi Health, Inc., headquartered in Palo Alto, California. The company has raised more than $250 million from institutional investors including Emerson Collective, Goodwater Capital, Foresite Capital, and Serena Ventures, alongside a handful of celebrity backers such as Tory Burch and Amy Schumer. Its most recent funding round valued the business above $1 billion — the kind of repeated institutional due diligence that a shell operation doesn't attract.

Midi employs licensed clinicians in the states where it operates, bills major health insurers directly for hormone therapy visits, and is BBB accredited. None of that makes it flawless — a real, well-funded company can still generate real complaints, and Midi has some worth knowing about before you hand over your insurance card or your credit card. Those specifics are below, each linked to where this research found it.

Has Midi Health been sued, or named in any legal action?

Not in the lawsuit wave you may be thinking of. In April 2025, Eli Lilly filed federal lawsuits against four telehealth companies selling compounded versions of its GLP-1 drugs — Henry Meds, Mochi Health, Willow Health, and Fella Health — over marketing claims around compounded tirzepatide, according to contemporaneous coverage from CNBC and NPR. Midi Health is not named as a defendant in any of those four complaints, and no coverage of that lawsuit wave found during this research — legal-trade press included — lists Midi among the defendants.

That doesn't mean Midi has been free of litigation. Two separate federal lawsuits have been filed against Midi Health, Inc. itself in the Northern District of California. The first, N.C. et al v. Midi Health, Inc., was filed in March 2025 by two plaintiffs identified only by initials, alleging fraud. The plaintiffs voluntarily dismissed the case themselves that September, and the docket shows no judgment, settlement terms, or admission of wrongdoing — a voluntary dismissal this clean typically means the case was dropped or resolved privately, not that Midi was found liable for anything.

The second suit, Baker v. Midi Health, Inc., was filed that December. The public docket confirms the filing, but the underlying complaint wasn't accessible during this research, so its specific allegations and current status should be confirmed directly on the court record before you treat it as resolved either way.

Separately, Midi ran into BBB National Programs' National Advertising Division in early 2026. NAD challenged an Instagram ad claiming women would "join the 91% of patients who find relief within 2 months," and rather than defend the number, Midi told NAD it had permanently discontinued the claim, according to NAD's published decision. That's not a lawsuit — NAD is a self-regulatory advertising body, not a court — but it is a documented instance of Midi walking back a specific result claim it could not, or chose not to, defend.

Has the FDA taken any action against Midi Health?

No FDA warning letter addressed to Midi Health or joinmidi.com turned up in FDA's public warning-letter database or in reporting on the FDA's 2026 enforcement sweeps against compounded-GLP-1 marketers, which named dozens of smaller telehealth and med-spa operators but not Midi. That is a genuinely different regulatory posture than several higher-profile compounded-GLP-1 telehealth brands carry right now.

One caveat worth stating plainly: the absence of a warning letter isn't an FDA endorsement, and this check relied on secondary reporting plus keyword searches of FDA's letter index rather than a guaranteed-complete database export. FDA's warning-letter database is public and searchable by company name — worth confirming yourself before enrolling if this matters to you.

What's Midi Health's BBB rating, and what do complaints actually say?

Midi holds a B rating with the Better Business Bureau and has been BBB accredited since March 2024, per its current BBB.org profile. The profile lists 151 complaints as of this writing — a nontrivial number for a company this size, though B is a middling-to-decent grade, not the F rating some compounded-GLP-1 telehealth brands carry.

The complaint theme that stands out, given Midi's core pitch of billing your insurance, is billing confusion: patients report being told they're in-network, then receiving a self-pay bill anyway, or hitting an unexpected charge after a visit. A second recurring theme is prescription and portal delays — one reviewer described weeks-long waits for medication to become available through Midi's system with no responsive way to follow up. A smaller number of complaints describe dissatisfaction with a specific clinical decision, such as a dose change a patient felt was made without adequate explanation.

On Trustpilot, Midi's independent rating runs noticeably higher: around 4 out of 5 stars from more than 1,200 reviews. Roughly three-quarters of reviewers leave five stars, and a smaller cluster leaves one star — largely echoing the same billing and delay complaints visible on BBB. Reading only one of the two ratings gives you a skewed picture; reading both together is closer to the truth.

What does Reddit say about Midi Health?

Less than you might expect, and less than exists for larger compounded-GLP-1 brands. A search across r/menopause, r/Perimenopause, and r/WomensHealth did not surface a meaningful, verifiable body of Midi-specific threads through standard search tools during this research — Reddit's own search and general search-engine indexing of Reddit are both notoriously incomplete, and this wasn't a logged-in, exhaustive manual sweep of each subreddit. That's a real limitation, not a finding of silence: it means you should search Reddit yourself before treating either "no complaints exist" or "lots of complaints exist" as established. If you do, weight specific, detailed accounts — dates, what was billed, what a provider actually said — over a one-line review with no detail behind it.

What are the most common patient complaints?

• Insurance billing confusion — being told a visit is in-network, then billed as self-pay. This is the top theme on both BBB and Trustpilot, and the most consequential given Midi's insurance-first pitch.
• Prescription and portal delays — medication or refill requests taking weeks to process, paired with slow customer-service response.
• Dissatisfaction with a specific clinical decision, most often a dose or medication change a patient felt wasn't explained clearly.
• No bundled labs — you'll need to arrange your own bloodwork through a primary care provider or a third-party lab service.
• Not available in all 50 states, so whether Midi is even an option depends on where you live.
• The GLP-1 program is self-pay only — insurance covers HRT visits but not the compounded weight-management medication.

Are Midi Health's providers real, licensed menopause specialists?

Yes, with the normal caveat that individual experience varies by clinician. Midi's clinician page states its providers are board-certified nurse practitioners, certified nurse midwives, physicians (MD or DO), and naturopathic doctors, and that the company prioritizes candidates with menopause-specific training or certification from The Menopause Society (formerly NAMS), on top of an internal training program. Requiring an active, unrestricted state license is standard for any legitimate telehealth operation and doesn't by itself distinguish Midi from competitors — what does is the stated hiring preference for menopause-trained or NAMS-certified clinicians specifically, rather than general-practice providers picking up menopause visits as one specialty among many.

There's no independent public registry that lets a patient verify what share of Midi's roster actually holds NAMS certification versus general licensure plus internal training, so treat the company's own framing as a claim worth weighing rather than an audited fact. You can ask your own assigned provider about their specific credentials during intake — a menopause-focused platform should have no trouble answering that question directly.

Is Midi Health's compounded GLP-1 program in a regulatory gray area?

It sits in the same evolving regulatory lane as every compounded-GLP-1 telehealth program right now, not a Midi-specific problem. Midi fills its compounded semaglutide and dual-action GLP-1/GIP prescriptions through a 503A compounding pharmacy — a category of pharmacy licensed to compound a medication for one named patient against one specific prescription, regulated primarily at the state board of pharmacy level rather than through FDA product approval.

The ground under that model has shifted. FDA removed semaglutide and tirzepatide from its official drug shortage list during 2025, which eliminated the shortage-based justification 503A pharmacies had relied on to compound near-copies of the branded drugs at scale; compounding remains legal but is supposed to track individual patient need rather than blanket production. Separately, on April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list entirely, with a public comment period that closed at the end of June 2026 and no final rule issued as of this writing. None of that is unique to Midi — it affects every compounding pharmacy in the country — but it means the compounded GLP-1/GIP option in Midi's GLP-1 program sits on less stable regulatory ground than Midi's core HRT business, which relies on standard prescriptions rather than compounding.

Any data privacy or HIPAA issues?

One document is worth flagging, though this research could not confirm its full contents. A filing titled "Midi Health, Inc." appears in the New Hampshire Department of Justice's security breach notification records, dated March 2025 — New Hampshire requires companies to notify the state attorney general when a data breach affects any state resident. The underlying PDF returned an access error during this research, so the number of people affected, the type of data involved, and the cause were not confirmed. This needs a direct check of New Hampshire's breach-notification portal before you treat it as more than "a filing exists."

Beyond that filing, no FTC enforcement action or Health Breach Notification Rule finding against Midi Health turned up in this research. Midi's own privacy notice describes standard HIPAA-covered-entity practices, and — like most direct-to-consumer telehealth platforms — its terms include a binding arbitration clause with a class-action waiver, meaning a dispute over your data or your bill is contractually routed to individual arbitration rather than a lawsuit you could join with other patients.

Red flags to check yourself before you enroll

• Call your insurer directly and confirm Midi is in-network for your specific plan before your visit — BBB's complaint pattern centers on patients told they were covered who were later billed as self-pay.
• Ask your assigned clinician directly about their menopause-specific training or NAMS certification — Midi states this as a hiring priority, but it isn't independently auditable per provider.
• If you're considering the compounded GLP-1 or GLP-1/GIP option, ask which 503A pharmacy fills your prescription and confirm its state license is current.
• Read the cancellation and refund terms before entering a card number, and keep a screenshot of your cancellation confirmation if you ever cancel.
• Confirm current state availability directly at joinmidi.com — Midi does not operate in all 50 states, and coverage areas shift as the platform expands.
• Don't rely on a single rating source. BBB, Trustpilot, and the NAD decision each tell a different piece of the same story — read more than one before deciding.

The bottom line: is Midi Health legit?

Yes. Midi Health is a legitimate, well-funded, licensed telehealth company — not a scam, and not part of the 2025 Eli Lilly lawsuit wave that hit several of its higher-profile compounded-GLP-1 competitors. It bills real insurance, employs real licensed clinicians, and has been reviewed by BBB National Programs' advertising watchdog — itself a sign of a company operating in a regulated, monitored space rather than flying under the radar.

The honest asterisks: two of its own federal lawsuits, one dropped and one unresolved as of this writing; a marketing claim it discontinued rather than defended; a B — not A — BBB rating driven largely by insurance-billing confusion; and the same compounded-GLP-1 regulatory uncertainty every telehealth company in this category now faces. None of that adds up to "stay away." It adds up to confirming your insurance coverage before your first visit, asking your provider about their credentials, and reading the cancellation terms — the same due diligence worth doing with any telehealth company, applied specifically to where Midi's own record shows friction.